Philogen S.p.A.
Philogen S.p.A. is a Italy-based biotechnology company running 8 late-stage cancer trials of Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma and basal cell carcinoma.
Overview
Philogen S.p.A., based in Siena, Italy, is a biotechnology company listed as BIT:PHIL. Philogen is a biotechnology company developing targeted cancer therapeutics based on antibodies and small molecules directed at the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma, basal cell carcinoma and sarcomas. The largest, NCT04443010 (Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma), plans to enrol 226 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyHangzhou Hanx Biopharmaceuticals
Shares Glioma & glioblastoma, Melanoma and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyQBiotics
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyRanok Therapeutics (Hangzhou)
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Glioma & glioblastoma, Melanoma and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Melanoma and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma and the tag ctgov-sponsor.